336 related articles for article (PubMed ID: 25130198)
1. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.
Gupta S; Zhang J; Jerusalem G
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):929-40. PubMed ID: 25130198
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
3. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
Gao S; Barber B; Schabert V; Ferrufino C
Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
[TBL] [Abstract][Full Text] [Related]
4. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
7. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK; Seidman AD
Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
9. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
10. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
André F; Neven P; Marinsek N; Zhang J; Baladi JF; Degun R; Benelli G; Saletan S; Jerusalem G
Curr Med Res Opin; 2014 Jun; 30(6):1007-16. PubMed ID: 24490834
[TBL] [Abstract][Full Text] [Related]
11. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
Lin PL; Hao Y; Xie J; Li N; Zhong Y; Zhou Z; Signorovitch JE; Wu EQ
Cancer Med; 2016 Feb; 5(2):209-20. PubMed ID: 26686532
[TBL] [Abstract][Full Text] [Related]
12. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey.
DeKoven M; Bonthapally V; Jiao X; Ganguli A; Pathak P; Lee WC; Ray S
J Comp Eff Res; 2012 Sep; 1(5):453-63. PubMed ID: 24236422
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
14. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
16. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer.
Fedele P; Orlando L; Schiavone P; Calvani N; Caliolo C; Quaranta A; Nacci A; Cinieri S
Crit Rev Oncol Hematol; 2015 Jun; 94(3):291-301. PubMed ID: 25624176
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
20. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
